Fig. 1

Trends in age- and sex-standardized prevalence of exposure to potentially inappropriate prescriptions of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Benzodiazepines (BZDs), Anticholinergics drugs (ACH) and AntiHyperTensive drugs (AHT), France, 2011–2019. Hypnotic Z-drugs (Z-drugs); Long-acting benzodiazepines (Long-acting BZDs); Short- and intermediate- acting benzodiazepines three or more dispensations during the year (Repeated other BZDs); Concurrent use of benzodiazepine and opioids (BZD + opioid); Concurrent use of at least two benzodiazepines (BZD + BZD); Concurrent use of benzodiazepines and hypnotic Z-drugs (BZD + Z-drug), First-generation antihistamine (ANTI-H1), Tricyclic antidepressants (TCAs); Concurrent use of two NSAIDs (NSAID + NSAID); NSAIDs three or more dispensations during the year (Repeated NSAIDs); Concurrent use of NSAID and antiplatelet agents (NSAID + APT); concurrent use of NSAID and vitamin K antagonists or non-vitamin k antagonist oral anti-coagulant (NSAID + OAC); concurrent use of β-blockers and verapamil or diltiazem (BB + calcic.inhib), selective calcium channel blockers with immediate release (CCB)